coordinates AMP kinase-mediated lung vascular repair.
ENDOTHELIAL DYSFUNCTION occurring with a severely compromised vasculature, such as is observed with the acute respiratory distress syndrome (ARDS), contributes to the high mortality rate associated with this disease. However, few therapeutic options are available to treat vascular injury and are often limited to supportive care. Strategies which enhance endothelial repair are not available.
A functional endothelial barrier relies on cell-cell adhesions that organize individual endothelial cells into the endothelium which in turn forms the lining of blood vessels. This lining regulates movement of molecules and fluids between the blood and interstitium to limit vascular permeability. In the lung, maintenance of a tight barrier and efficient gas exchange depend on the capillary endothelium where dynamic cell-cell adhesions respond quickly to changes in alveolar volume and vascular pressure. The balance of regulatory molecules that cluster at these sites of cell-cell adhesion determines the nature of adherens junctional complexes and subsequently tightness of the barrier. Vascular endothelial (VE)-cadherin and epithelial cadherin (E-cadherin) are well described in the lung and are considered important regulators of cell-cell adhesion (12, 37, 43) . N-cadherin is also expressed in the lung; however, its role in regulating vascular permeability is not as well defined. Resolving the contribution of N-cadherin to endothelial barrier integrity and pulmonary vascular function is the focus of this study.
Cadherins are the family of adhesion molecules responsible for homotypic calcium-dependent cell-cell adhesion. N-cadherin, also known as cadherin 2, is a classical type 1 cadherin comprised of five extracellular cadherin repeats, a single transmembrane spanning region, and a highly conserved cytoplasmic tail (31, 33, 42) . In addition to its role as an adhesion molecule, N-cadherin has other, similarly important, functions in vascular biology. It serves as a signaling scaffold that organizes regulators of cell proliferation and gene expression. And during vasculogenesis, it maintains the endothelial-epithelial sheet required for complex vascular formation (21, 30) . Although N-cadherin is important in the cell proliferative aspect of vascularization during development, it also serves as a key regulator of cell movement and is essential for the maintenance of adult tissue (16, 44) .
We recently increased understanding of N-cadherin function in endothelium, wherein we found N-cadherin colocalized with AMPK␣1 in a signaling complex important for vascular repair. Activation of AMPK␣1 was necessary for reestablishment of the endothelial barrier in response to LPS-induced damage and for resolution of LPS-induced pulmonary edema and increased permeability in vivo (11, 24, 32) . Our current data provide evidence that AMPK␣1 function is linked to N-cadherin through the cadherin's cytoplasmic tail and that this interaction is necessary for AMPK␣1-mediated pulmonary response to endothelial injury. These findings increase understanding of N-cadherin's role in the lung and suggest this cadherin serves as a signaling scaffold essential for orchestrating AMPK␣1-mediated microvascular repair.
MATERIALS AND METHODS
Antibodies to phospho-Thr172 AMPK␣, total-AMPK␣, and sepharose-conjugated AMPK␣ were purchased from Cell Signaling Technology (Beverly, MA). Taq DNA polymerase came from New England Biolabs (Ipswich, MA). Antibody to green fluorescent protein (GFP) was obtained from Origene (Rockville, MD). Antibodies to ␤-actin, normal mouse and rabbit IgGs, and protein A/G sepharose were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). N-cadherin antibody used as an extracellular neutralizing antibody was obtained from Sigma-Aldrich (St. Louis, MO). Dulbecco's Modified Eagle Medium (DMEM), PenStrep, Multiscribe reverse transcriptase, cell extraction buffer, and Alexa Fluor 488 and 546 secondary antibodies came from Invitrogen Life Technologies (Grand Island, NY). Antibodies directed to N-cadherin N-terminal and Ncadherin C-terminal domains came from GeneTex (Irvine, CA). Secondary antibodies (goat antirabbit and goat antimouse IgGs) conjugated to horseradish peroxidase (HRP), Bradford reagents, Laemmli sample buffer, and TGX gels came from BioRad (Hercules, CA). Polyvinylidene difluoride (PVDF) membranes were purchased from Millipore (Billerica, MA). Pierce Biotechnology Super Signal enhanced chemiluminescence system was used for signal visualization (Rockford, IL). The Pseudomonas aeruginosa LPS used for all studies was obtained from Sigma-Aldrich. Unless otherwise noted, all other materials and reagents were obtained from Sigma-Aldrich.
Animals. All animal experiments were performed using male Sprague-Dawley rats (200 -250 g, Charles River, Wilmington, MA) following a protocol approved by the Animal Care and Use Committee of the University of Alabama at Birmingham and in accordance with the National Institutes of Health Guidelines on the Care and Use of Laboratory Animals.
Isolated perfused lungs. Animals were anesthetized and following sternotomy, the pulmonary artery, left atrium, and trachea were cannulated. The lungs and heart were excised en bloc and suspended from a force transducer (FT03 Grass Instruments, Middleton, WI) for continuous measurement of lung weight. Lungs were ventilated with room air at a rate of 70 cycles per minute and perfused at constant flow with Earle's balanced salt solution containing 4% BSA (pH 7.4, 37°C). Baseline values were established prior to the addition of LPS (10 g/ml), 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR; 1 mmol/l), metformin (12 mmol/l), or the Ncadherin antagonist 4-(1,2,3,4-thiatriazol-5-ylamino)phenol (TAP, 50 mol/l). Filtration coefficients (Kf) were taken at baseline, 30, 60, 90, and 120 min. K f measurements were calculated as the rate of weight gain obtained after a 100-mm H 2O increase in pulmonary venous pressure and were normalized to lung dry weight (g). Hemodynamic parameters (pulmonary artery, capillary, venous, and airway pressures) and lung weight gain were determined with ADInstruments PowerLab 8/30 and LabChart pro software. pH, pO2, and pCO2 were monitored during experiments with an OPTI Medical Systems Blood Gas Analyzer (Roswell, Georgia).
Histology. Lungs from each group were chosen at random and perfusion fixed with 10% formalin at 250-mm H2O airway pressure and 150-mm H 2O vascular pressure prior to embedding in paraffin. Sections were cut into 5-m slices and stained with hematoxylin and eosin to evaluate changes in morphology.
Cell culture. Rat pulmonary artery microvascular endothelial cells (PMVECs) were isolated, characterized, and cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin as described previously (11, 29) .
Western blot analysis. Western blot analysis was performed as described previously (26) . Briefly, cells were lysed in cell extraction buffer, sonicated, then centrifuged to remove insoluble material. Protein concentrations in the resulting supernatants were determined by Bradford using BSA as a standard. Equal amounts of protein were resolved with 8% TGX gels and SDS gel electrophoresis and then transferred onto PVDF membranes. Membranes were probed with pThr172 AMPK␣ (1:1,000), total AMPK␣ (1:1,000), N-cadherin antibodies (1:500), or ␤-actin (1:2,000) antibodies followed by detection with HRP-conjugated goat antirabbit or goat antimouse IgG. Bands were visualized by enhanced chemiluminescence and quantified by AlphaEaseFC software (Alpha Innotech, San Leandro, CA). Each experiment was carried out three or more times.
Coimmunoprecipitations. For immunoprecipitations, confluent PMVECs were rinsed with Hanks' balanced salt solution before addition of ice-cold lysis buffer. Initial extracts were precleared with normal IgG and Protein A/G Plus Sepharose. To immunoprecipitate proteins, N-cadherin antibody or AMPK␣ conjugated sepharose was added to the cell extract and rocked overnight. Total immunoprecipitated protein was recovered by resuspending the Protein A/G Sepharose pellet in 3% SDS and heating briefly. Protein A/G Sepharose then was pelleted by centrifugation, and the supernatant containing SDSsoluble material was reserved. A methanol-chloroform phase separation step was performed on the supernatant to remove nonprotein contaminants. The purified protein pellet was washed once in methanol. The protein pellet was resuspended in 2X SDS sample buffer and heated briefly. Aliquots were frozen at Ϫ80°C or used immediately for SDS-PAGE/Western analysis.
Viral constructs and stable transduction of N-cadherin shRNA. Expression of AMPK␣1 was reduced in PMVECs by a short-hairpin RNA (shRNA)-mediated approach as we have previously described (10, 11) . For reduction of N-cadherin expression, shRNAs were annealed and cloned into a pMA2858, a lentiviral vector, for constitutive PolII (cytomegalovirus, CMV) promoter-driven expression of shRNA constructs in the context of the murine miR155 (1) . shRNA expression in infected cells was followed by Enhanced GFP (EGFP) fluorescence. After verification of inserts by sequencing, lentivirus-containing supernatants were generated by CaPO 4-mediated transduction of 293FT cells with vector and helper plasmids (psPAX2 and pMD2.G). Forward and reverse sequence sets for each of the six shRNAs used rCadh1FTG-CTGTATATCAGGAACTTTGCCTGCGTTTTGGCCACTGAC-TGACGCAGGCAATTCCTGATATA, rCadh1RCCTGTATATCA-GGAATTGCCTGCGTCAGTCA-GTGGCCAAAACGCAGGCA-AAGTTCCTGATATAC, rCadh2FTGCTGACCTGATTCTGACAA-GCTCTTGTTTTGGCCACTGACTGACAAGAGCTTCAGAAT-CAGGT, rCadh2RCCTGACCTGA-TTCTGAAGCTCTTGTCAGTC-AGTGGCCAAAACAAGAGCTTGTCAGAATCAGGTC, rCadh3F-TGCTGTGATGAAGATGCCCGTTGGAGGTTTTGGCCACTGACT-GACCTCCAACGCATCTTCATCA, rCadh3RCCTGTGATGA-AGATGCGTTGGAGGTCAGTCAGTGGCCAAAACCTCCAAC-GGGCATCTTCATCA, rCadh4FTGCTGTGCATGTGCCCTCA-GGTGAAAGTTTTGGCCACTGA-CTGACTTTCACCTGG-GCA-CATGCA, rCadh4RCCTGTGCATGTGCCCAGGTGAAAGTCAGT-CAGTGGCCAAAACTTTCACCTGAGGGCACATGCAC, rCadh5F-TGCTGAACAGACCCATTCC-AAACCTGGTTTTGGCCACTG-ACTGACCAGGTTTGATGGGTCTGTT, rCadh5RCCTGAACAG-ACCCATCAAACCTGGTCAGTCAGTGGCCAAAACCAGGTTTG-GAATGGGTCTGTTC, rCadh-6FTGCTGATAACTGTCACAG-ACACCGTGGTTTTGGCCACTGACTGACCACGGTGTGTGA-CAGTTAT, rCadh6RCCTGATAACTGTCACACACCGTGGTC-AGTCAGTGGCCAAAACCACGGT-GTCTGTGACAGTTA. The shRNA which produced the greatest decrease in protein (no. 3) was chosen for further study. The cytoplasmic (aa 753-906) domain of N-cadherin was replaced with EGFP to generate (⌬N-cad) cells. Overexpression of the fusion protein was achieved by transducing target cells with rv.3617, a derivative of pMA1662, a hygromycin-resistant retroviral vector (36) .
Polymerase chain reaction. PMVECs were cultured to confluence. Total RNA was isolated by gently titrating the cells with TRIzol. This extract was transferred to sterile microcentrifuge tubes and total RNA was recovered as per the manufacturer's protocol: following chloroform-induced phase separation, the aqueous phase was recovered, and total RNA precipitated with isopropanol. Total RNA was recovered by centrifugation, and pellets washed once with ice-cold 80% ethanol, vacuum dried, and resuspended in DEPC-treated water. Purity was assessed by sample absorbance at 260 and 280 nm; RNA content was measured by 260-nm absorbance. All RNA samples were brought to a final concentration of 1-g total PMVEC RNA per microliter of water and stored at Ϫ80°C. cDNA was produced by Multiscribe reverse transcriptase, random primers, and the manufacturer's protocol. PCR amplification of target cDNAs were performed on an Eppendorf thermal cycler following the manufacturer's protocol. Forward and reverse primers were identified by the PrimerQuest algorithm of Integrated DNA Technologies. Each amplification reaction was analyzed with 1% agarose gel electrophoresis with Trisbuffered Earle's (TBE) as a running buffer and ethidium bromide as a visualization agent under 302-nm ultraviolet irradiation. Gel images were recorded and analyzed with an Alpha Innotech Multi-Imager and FluoroChem 8000 software. Primer sets for PCR (rat) ␤-actin include the following: F:CAACTGGGACGATATGGAGAAG, R:CTC-GAAGTCTAGGG-CAACATAG; amplicon: 442 bp, from nucleotides 309 to 751; N-cadherin F:GAGAGGAAGACCA-GGAC-TATGA R:CAGTCATCACCACCACCATAC; amplicon: 385 bp, from nucleotides 2672 to 3057; AMPK ␣1 F:ACCATTCTTGGTT-GCCGAAACACC R:GGTTCTTCCTTCGCACACGCAAA-T amplicon: 224 bp, from nucleotides 1125 to 1348.
Transendothelial electric resistance. PMVEC barrier integrity was measured with an electric cell-substrate impedance sensing (ECIS) system (Applied Biophysics, Troy, NY) as described in detail (10, 11, 29) . Briefly, PMVECs (40 ϫ 10 3 cells/mm 2 ) were plated onto 8W10E arrays in normal culture medium and used when resistances reached Ϯ600 -900 ohms, usually 2-3 days postseeding. Baseline resistances were established prior to the addition of LPS (250 g/ml), AICAR (1 mmol/l), metformin (12 mmol/l), or the N-cadherin antagonist 4-(1,2,3,4-thiatriazol-5-ylamino)phenol (TAP, 50 mol/l). Resistances were obtained every 15 min for the duration of the experiments. Studies were repeated at least five times.
PMVEC wound healing. The endothelial response to wounding was evaluated by determining the rate (velocity) of gap closure in scratchwounded PMVEC monolayers. Cells were plated onto sterile 25-mm glass coverslips and grown to confluence over 3-4 days. Monolayers were scratched with a sterile 200-l pipette tip, and coverslips fitted into an Attofluor cell chamber (Life Technologies). Experiments were performed in cell culture medium under environmentally controlled conditions (5% CO2, 37°C) with a Pathology Devices LiveCell stage top incubation system (Westminster, MD). Baseline velocities were established prior to the addition of LPS (250 g/ml), AICAR (1 mmol/l), or metformin (12 mmol/l). Images were taken with a ϫ10 objective at 10-min intervals for 24 h with a Nikon Eclipse Ti microscope and Nikon Elements software (Nikon Instruments, Melville, NY). Velocities were determined by choosing 10 -12 cells located on either side of the leading edge of the gap and measuring the distance covered by each of the cells every 10 min until the gap closed. Individual velocities were averaged over several time points (usually 1-2 h) to get an average velocity for each treatment group. The averaged velocities of multiple experiments are presented in graph form for quantitative comparison. Distances were converted to velocity (distance/time) with the Elements software object tracking module. Studies were repeated at least five times.
Immunocytochemistry. Cells were seeded onto 12-mm coverslips and grown to confluence over 4 -5 days. After methanol fixation, and permeabilization in 0.1% Triton X-100, cells were incubated at 4°C overnight with either N-cadherin antibody diluted (1:250) in PBS or AMPK␣ antibody diluted (1:500) in PBS. Secondary antibody (Alexa Fluor goat antimouse 488 for N-cadherin or Alexa Fluor 546 donkey antirabbit for AMPK␣) was incubated at 1:500 for 1 h. Cells were mounted onto glass microscope slides with Dako (Carpinteria, CA) fluorescent mounting medium. Dako mounting medium for IgG controls contained DAPI to counter stain nuclei. Images were obtained with a Nikon Eclipse Ti microscope fitted with a ϫ60 oil-immersion objective and Nikon Elements software (Nikon Instruments). Studies were repeated three times.
Graphing and statistical analysis. Data are reported as means Ϯ SE. Statistical analysis was performed by a Student's t-test, one-way, or two-way ANOVA with post hoc comparisons as appropriate. In all cases, values of P Ͻ 0.05 were considered significant. Data were graphed with GraphPad Prism 5.01 for Windows (GraphPad Software, San Diego, CA).
RESULTS
Silencing N-cadherin expression does not alter AMPK␣1 levels in lung capillary cells. Using shRNA and a lentiviral vector system, we generated six PMVEC lines stably transduced with shRNA spanning six different regions of N-cadherin mRNA. shRNA directed against region no. 3 produced decreases in N-cadherin mRNA (Fig. 1A ) and protein content (Fig. 1C ), which were statistically significant ( Fig. 1, B and D). Studies were repeated over several passages to confirm stability of the knockdown. Since N-cadherin expression is known to regulate the expression of other proteins, PMVECs stably transduced with shRNA3 were compared with cells expressing shRNA to AMPK␣1. Silencing expression of either AMPK␣1 or N-cadherin did not alter expression of the other protein ( N-cadherin contributes to AMPK-mediated rescue of endothelial barrier resistance. In preparation for our barrier resistance studies, we used antibody raised against the extracellular N-terminal domain of N-cadherin to determine the point in resistance where N-cadherin adhesions contribute to development of the endothelial barrier ( Fig. 2A ). This antibody acts as a neutralizing antibody that blocks N-cadherin to N-cadherin N-terminal (extracellular) trans interactions. Transendothelial electrical resistance measurements were taken at 15-min intervals over 24 h to monitor the increase in resistance. In the presence of the antibody, barrier resistance failed to increase beyond Ϯ900 ohms ( Fig. 2A) . The neutralizing effect of the antibody was confirmed by the decrease in resistance observed near the end of the experiment. This observation has been reported by others and signifies inhibition of N-cadherin extracellular interactions which is incompatible with cell growth (3, 9, 47) . Thus resistance ranges between 600 -900 ohms were used for the remaining studies. Parallel studies using cells expressing shRNA to AMPK␣1 confirmed a functional link between AMPk␣1 and N-cadherin as these cells were insensitive to the anti N-cadherin antibody (Fig. 2B) . Moreover, these results are consistent with our previous finding that AMPK␣1 activity is necessary for N-cadherin-mediated barrier repair (11) .
We next sought to determine whether N-cadherin contributed to AMPK-mediated restoration of an LPS-injured PM-VEC monolayer. Measurements of transendothelial electrical resistance indicated that LPS decreased resistance of control and shRNA N-cadherin monolayers by 56 and 43% at 24 h, respectively (Fig. 2, C and D) . AMPK was stimulated with AICAR. Both cell lines were sensitive to AMPK-mediated restoration of barrier resistance in the presence of LPS (Fig.  2E) . However, the extent of barrier repair was attenuated in shRNA N-cadherin expressing PMVECs compared with wildtype monolayers (Fig. 2E) , suggesting N-cadherin involvement in the AMPK dependent response to LPS.
N-cadherin contributes to AMPK-mediated endothelial barrier repair. N-cadherin is known to regulate cell movement, which is an important component of endothelial barrier repair. Thus scratch-wound studies were performed to assess the role of N-cadherin in PMVEC reestablishing an intact monolayer. LPS caused a decrease in the rate of gap resealing (velocity) in both wild type and shRNA expressing PMVEC monolayers (Fig. 3A) . Addition of AICAR to stimulate AMPK increased the rate of resealing in LPS-treated control cells to nontreated levels (0.014 Ϯ 0.0016 vs. 0.015 Ϯ 0.0017 m/s, respectively) and partially rescued the rate of resealing in LPS-treated shRNA expressing monolayers (0.0090 Ϯ 0.0013 m/s) (Fig.  3A) . Velocity traces obtained from a typical experiment are shown in Fig. 3B . These data are consistent with the resistance studies and implicate N-cadherin involvement in AMPK-mediated endothelial barrier repair, as knocking down N-cadherin impaired the ability of AMPK to reseal the monolayer.
N-cadherin/GFP fusion protein localizes to cell-cell borders, but does not interact with native N-cadherin. N-cadherin protein-protein interactions are complex. This cadherin forms trans homotypic interactions via its N-terminal domain and the N-terminal domains of N-cadherin molecules located on adjacent cells and cis homotypic interactions with adjacent Ncadherin molecules located within the same cell membrane via C-terminus to C-terminus intracellular interactions. The C-terminus domain also acts as a scaffolding protein which interacts with other adherens' junction proteins. Since shRNA to Ncadherin reduced, but did not block the ability of AMPK stimulation to resolve LPS-induced endothelial injury, we questioned whether N-cadherin's link to the beneficial actions of AMPK involved its intracellular domain. For these studies, we truncated N-cadherin by removing its C-terminal domain (aa 753-906) and replacing it with GFP. This construct was incorporated into a retroviral vector system and stably transduced into PMVECs. The resulting cell line, designated ⌬N-cad, was then used to determine the effect of disrupting the intracellular interactions of N-cadherin during AMPK stimulation.
Native N-cadherin coimmunoprecipitated with AMPK␣ in wild-type cells, but not in cells expressing the N-cadherin/GFP fusion protein, indicating the physical link between N-cadherin and AMPK␣1 required the intracellular domain of the cadherin (Fig. 4A) . The N-cadherin/GFP construct immunoblotted with antibodies directed against the N-terminus of N-cadherin as expected, but did not interact with the native full-length Ncadherin as shown by a lack of immunoblotting using antibody specific for the C-terminus of N-cadherin (Fig. 4B) . Fluorescence studies revealed that the truncated ⌬N-cad/GFP protein localized to regions of cell-cell contact similar to the native full-length protein (Fig. 4C) . Dual fluorescence staining of N-cadherin and AMPK␣ confirm that AMPK␣ no longer associated with N-cadherin or the cell membrane in ⌬N-cad cells (Fig. 4D ). Taken together, these studies provide evidence that the ⌬N-cad/GFP fusion protein translocates to the appropriate membrane location, but is unable to interact with AMPK␣1 or the native full-length N-cadherin. Moreover, these data indicate that AMPK␣ association with the cell membrane depends on an intact N-cadherin complex, suggest- ing N-cadherin serves as a scaffolding protein for AMPK␣. These studies also validate this construct as an appropriate tool for studying the effect of disrupting N-cadherin intracellular interactions on AMPK function in lung endothelium.
Loss of N-cadherin intracellular interactions blocks AMPKmediated restoration of a tight PMVEC barrier. To establish the importance of N-cadherin's intracellular domain in coordinating AMPK-driven barrier resealing, transendothelial resistance studies were repeated by using the ⌬N-cad cells. LPS caused a decrease in resistance similar to the cells expressing the shRNA against N-cadherin and wild-type controls. However, the ⌬N-cad cells were refractory to rescue of barrier resistance by AMPK stimulation. For these studies, we used two pharmacologic tools to activate AMPK. In addition to AICAR, a direct activator of AMPK, we also used the biguanide, metformin, which is an indirect activator of AMPK. In control cells, AICAR and metformin increased barrier resistance in LPS-treated cells to untreated levels (Fig. 5, A and B) . In contrast, the resistance in LPS-treated ⌬N-cad cells did not recover following AMPK stimulation and remained decreased similar to LPS-only-treated resistances (Fig. 5, C and D) . We quantified the differences in the response to AMPK stimulation by averaging the last five values obtained during five to eight independent studies. These results confirm that AMPK stimulation failed to mitigate LPS-induced injury in the ⌬N-cad cells. Resistance values for LPS-treated control cells dropped to 623.1 Ϯ 35.9 ohms and for ⌬N-cad cells to 519.5 Ϯ 32.6 ohms. In response to AICAR or metformin, resistance in the control monolayers increased to near baseline levels (1,078.31 Ϯ 12.2 and 998.6 Ϯ 39.79 ohms, respectively; Fig. 5, E and F) . By contrast, ⌬N-cad cells were completely insensitive to AMPK stimulation with AICAR or metformin (505.70 Ϯ 32.5 and 415.8.6 Ϯ 12.23 ohms, respectively) where resistances remained near LPS-only-treated values (Fig. 5, E and F) . These results indicate that the cytoplasmic tail of N-cadherin is involved in mediating the AMPK response to LPS.
The N-cadherin C-terminal domain coordinates AMPKmediated wound repair in PMVECs. Figure 2 demonstrates N-cadherin involvement in the AMPK-mediated response to wound repair. We utilized the ⌬N-cad cells to determine whether this function of N-cadherin depends upon its ability to interact with intracellular proteins. The rates of gap closure are similar in the control and ⌬N-cadherin cells (0.012 Ϯ 0.008 vs. 0.012 Ϯ 0.0006 m/s, respectively; Fig. 6, A and C) . The ⌬N-cad cells differed from cells expressing the shRNA to N-cadherin in response to AMPK stimulation. In the shRNA expressing cells, AMPK stimulation partially restored the rate of repair in LPS-treated cells (Fig. 3A) , whereas LPS-treated ⌬N-cad cells did not respond to AMPK stimulation (Fig. 6C) .
Traces obtained from experiments demonstrate the movement of individual cells during a typical study. In control cells, LPS reduced the forward movement of cells. The addition of AICAR or metformin restores the rate of velocity to control values (Fig. 6B) . In contrast, the rate of gap resealing remains similar to LPS-only-treated cells in ⌬N-cad monolayers (Fig.  6D) . These data confirm the C-terminal tail of N-cadherin is necessary for AMPK dependent rescue of the LPS-injured endothelial barrier.
AMPK-mediated restoration of the endothelial barrier does not require N-cadherin localization at cell-cell margins.
Since disruption of N-cadherin's intracellular domain blocked the AMPK response in the scratch-wounding assay, we next used 4-(1,2,3,4-thiatriazol-5-ylamino) phenol (TAP), an extracellular N-cadherin antagonist, to determine whether disruption of N-cadherin membrane localization was sufficient to block AMPK-mediated rescue of barrier resistance. The effect of TAP on N-cadherin localization at cell-cell borders was evaluated by ⌬N-cad cells. Monolayers were grown to confluence Fig. 3 . N-cadherin contributes to AMPK-mediated wound healing in LPS-treated PMVECs. Confluent monolayers were scratch-wounded, and the rate of gap resealing (velocity) determined by time-lapse video microscopy with object tracking software. After establishing baseline velocities, cells were treated with LPS followed by the AMPK activator AICAR 2-4 h later. A: in control cells, LPS caused a decrease in the rate of gap closure which was restored to control levels by AMPK stimulation. LPS also caused a decrease in the velocity of gap closure in PMVECs stably transduced with the shRNA to N-cadherin (shRNA N-cad). However, in contrast to controls, AMPK stimulation partially reversed the decrease in the rate of gap resealing in these cells. B: representative velocity traces obtained from wild-type (control) and shRNA N-cad studies. Points depict movement of individual cells at the leading edge of the gap. Velocities of several cells from each treatment group were averaged over time (1-2 h), and data from multiple experiments were pooled for statistical analysis. Data are the means Ϯ SE, n ϭ 5. ###P Ͻ 0.001 (comparison of wild-type LPS and LPS ϩ AICAR groups); *P Ͻ 0.05 (comparison of shRNA N-cadherin LPS and LPS ϩ AICAR treated groups); statistics determined by two-way ANOVA with Bonferroni posttest.
and GFP localization was visualized with time-lapse fluorescence video microscopy. Under control conditions, The N-cad/ GFP fusion protein was restricted to regions of cell-cell contact. The addition of TAP to the monolayer resulted in diffusion of GFP-labeled N-cadherin away from cell borders toward a globally dispersed pattern across the cell membrane (Fig. 7A) , results consistent with TAP-induced disruption of N-cadherin membrane localization at cell-cell margins. Barrier resistance studies using TAP indicated that control cells were able to restore barrier resistance in the presence of AMPK stimulation (Fig. 7C) . In contrast, the ⌬N-cad cells were not able to restore barrier resistance with AMPK stimulation (Fig.  7D) . These data indicate that disruption of N-cadherin's cytoplasmic C-terminal tail, but not its membrane location, is sufficient to block AMPK stimulation from restoring the endothelial barrier.
Adherens junctions are formed in stages. Initial cell-cell contact involves the trans binding of cadherin ectodomains on adjacent cells. These interactions act as nucleation events that promote the clustering of cadherins located on the same cell membrane, which in turn promote intracellular protein-protein interactions and the formation of adhesion complexes (5, 14, 45, 46) . Since LPS is known to disrupt both extracellular and intracellular adherens protein interactions (15, 28, 48) , we questioned whether blocking N-cadherin extracellular interactions would affect the ability of AMPK stimulation to restore the barrier in the presence of LPS. Resistance studies indicate that AMPK stimulation with either AICAR or metformin was not able to restore the barrier in the presence of both LPS and TAP (Fig. 7, E and F) . These data are consistent with a role for N-cadherin in restoration of an LPS-disrupted endothelial barrier and also confirm the requirement for intact N-cadherin intracellular interactions in the AMPK response to endothelial injury.
Disrupting the C-terminal domain of N-cadherin reduces basal levels of active AMPK␣ in PMVECs.
Our studies to this point suggest the role of N-cadherin in the AMPK-mediated response to endothelial injury requires an intact N-cadherin Fig. 5 . N-cadherin intracellular domain contributes to AMPK-mediated repair of the endothelial barrier. Representative transendothelial electrical resistance traces of wild-type (control) PMVECs and PMVECs stably transduced with C-terminally truncated N-cadherin fused to GFP (⌬N-cad). Cells were treated with AMPK activators AICAR or metformin (Met) at times indicated by arrows. In controls, LPS attenuated the increase in resistance which was rescued by AMPK stimulation using AICAR (A) or Met (B). LPS also caused a decrease in resistance in ⌬N-cad cells. In contrast to controls, however, AMPK stimulation using AICAR (C) or Met (D) did not reverse the LPS-induced decrease in resistance in ⌬N-cad PMVECs. Resistance values obtained at the last five time points were pooled from five to eight independent studies to quantify differences in the response of LPS-treated control and ⌬N-cad cells to AICAR (E) and Met (F). Data values are means Ϯ SE; P Ͻ 0.001, using two-way ANOVA with Bonferroni posttest.
C-terminal domain. We next asked whether disruption of the intracellular interactions of N-cadherin altered basal (unstimulated) levels of active AMPK␣. Western blot analysis of total AMPK␣ and the active form of AMPK␣, which is phosphorylated at Thr-172 (pAMPK␣), indicated that disruption of the C-terminal domain of N-cadherin reduced the basal level of pAMPK␣ in ⌬N-cad expressing cells, but did not alter the total AMPK␣ content (Fig. 8A) . Quantification of the altered pAMPK␣ levels indicates that ⌬N-cad cells possessed 75% less pAMPK␣ than did control cells (Fig. 8B) . Interestingly, decreasing N-cadherin content alone, using shRNA to Ncadherin, was not sufficient to alter the basal levels of pAMPK␣ (Fig. 8B) or its overall content (Fig. 8C) . Thus basal AMPK␣ activity is dependent upon an intact N-cadherin Cterminal domain.
Disrupting the C-terminal domain of N-cadherin renders AMPK␣ insensitive to stimulation by AICAR and disrupts AMPK␣ localization to cell margins. Transendothelial resistance and wounding studies indicated that ⌬N-cad cells were insensitive to AMPK-mediated barrier repair. Moreover, the ⌬-cad cells possessed significantly less basal AMPK activity than control PMVECs. So we asked whether sensitivity of AMPK␣ to stimulation by AICAR was altered in the ⌬N-cad cells. Western blot analysis of the active form of AMPK␣ in control cells showed an eightfold increase in pAMPK␣ in response to 2 mM and 4 mM of AICAR at 4 h posttreatment (Fig. 8, D and E) . However, the ⌬N-cad cells did not demonstrate an increase in pAMPK␣ over the same time course and range of doses (Fig. 8, D and E) . These results are consistent with data in Fig. 4 where coimmunoprecipitations and fluorescence studies indicate that a pool of AMPK␣ that normally associates with the membrane and N-cadherin in control PMVECs is absent in ⌬N-cad cells. Taken together, these data indicate that N-cadherin coordinates AMPK␣ subcellular location, activity, and stimulability in lung endothelium.
N-cadherin contributes to repair of the LPS-injured lung.
To assess the role of N-cadherin in lung repair, we inhibited N-cadherin extracellular interactions in vivo. The isolated lung Fig. 6 . N-cadherin intracellular domain coordinates AMPK-mediated wound healing in LPS-treated PMVECs. Confluent PMVEC monolayers were scratch wounded and the rate of gap resealing (velocity) determined by time-lapse video microscopy using object tracking software. After establishing baseline velocities, cells were treated with LPS, followed by the AMPK activators AICAR or Met 2-4 h later. A: in control cells, LPS caused a decrease in the rate of gap closure which was restored to control levels by AMPK stimulation. C: LPS also caused a decrease in the velocity of gap closure in PMVECs stably transfected with the N-cadherin/GFP fusion protein (⌬N-cad). However, AMPK stimulation using AICAR or Met did not reverse the rate of gap resealing in these LPS-treated monolayers. Representative velocity traces obtained from wild-type (control) (B) and ⌬N-cad time-lapse studies (D). Points depict movement of individual cells at the leading edge of the gap. Velocities of several cells from each treatment group were averaged over time (1-2 h), and data from multiple experiments pooled for statistical analysis. Data in bar graphs are means Ϯ SE, n ϭ 5 independent experiments. P Ͻ 0.001 by one-way ANOVA with Bonferroni posttest.
technique was utilized to determine changes in lung permeability in response to LPS and TAP. Pulmonary vascular permeability as determined by an increase in the filtration coefficient (K f ) indicated that LPS caused a twofold increase in permeability by 30 min (Fig. 9A) . The addition of either AICAR or metformin to the perfusate reduced the increase in permeability to control levels by 60 min, and by the final K f measurement at 120 min, these lungs had K f s that were threefold lower than the LPS-only-treated group respectively) and similar to control W/D ratios of 6.1 Ϯ 1.08 (Fig. 9B) . Addition of the N-cadherin antagonist, TAP, to the perfusate caused a small increase in K f over time that was not statistically significant compared with controls (0.026 Ϯ 0.002 vs. 0.020 Ϯ 0.003 ml·min Ϫ1 ·cmH 2 O Ϫ1 ·g Ϫ1 dry weight at 120 min, respectively). When AICAR or metformin was added to the perfusate of LPS ϩ TAP treated lungs, no decrease in K f was observed for either group (Fig. 9C) . The W/D ratios revealed a similar trend. The W/D ratio of the LPS ϩ TAP group (8.42 Ϯ 0.65) was similar to the LPS ϩ TAP ϩ AICAR and the LPS ϩ TAP ϩ metformin groups (8.53 Ϯ 0.47 and 8.18 Ϯ 0.05, respectively), and all three groups were similar to LPS-onlytreated lungs (7.92 Ϯ 0.17; Fig. 9D ). These in vivo data are (⌬N-cad) , shRNA to AMPK␣1, or shRNA to N-cadherin, show disruption of the C-terminal domain of N-cadherin reduces basal levels of phosphorylated (active) AMPK␣. C: total AMPK␣ (tAMPK␣) levels are not altered by ⌬N-cad. Cells expressing shRNA against AMPK␣ used as negative control for pAMPK␣. D: disrupting the C-terminal domain of N-cadherin renders AMPK␣ insensitive to phosphorylation (pAMPK␣) by AICAR. Western analysis of PMVECs stably expressing ⌬N-cad shows AICAR (4 h) does not increase pAMPK␣ over a range of doses that increases pAMPK␣ in control cells. tAMPK␣ levels are not altered in the ⌬N-cad cells. E: analysis of pAMPK␣ indicates that 2 mM of AICAR causes a fourfold increase in pAMPK␣ in control cells, whereas pAMPK␣ remains at baseline levels in the ⌬N-cad cells. Data were quantified by densitometric analysis with Image J software. Changes in pAMPK␣ and tAMPK␣ were normalized to control levels in graphs in Fig. 7 , B and C. Data are means Ϯ SE, n ϭ 5-6 independent experiments. P Ͻ 0.001 by one-way or two-way ANOVAs with Bonferroni posttests. consistent with the in vitro (cell culture) studies which demonstrate AMPK-mediated lung repair is linked to N-cadherin.
Histology confirmed the effect of N-cadherin disruption on lung repair. Hematoxylin and eosin-stained lungs indicate congestion, alveolar distortion, and marked interstitial edema in the LPS-treated groups that was resolved by AMPK stimulation (Fig. 10A) . Damage similar to the LPS-treated lungs was observed in the lungs of the LPS ϩ TAP treated groups (Fig.  10B ). Stimulation of AMPK had no effect on the LPS ϩ TAP treated lungs, where damage to the alveolar segments remained readily observable in the LPS ϩ TAP ϩ AICAR and the LPS ϩ TAP ϩ metformin-treated lungs (Fig. 10B) .
DISCUSSION
AMPK is well recognized as a regulator of metabolic processes. As its name implies, this serine-threonine kinase is activated by 5=-AMP that competes with ATP for binding to the ␣,␤,␥ heterotrimeric complex's ␥ subunit. During periods of metabolic stress, ATP is depleted, increasing the AMP/ATP ratio. AMP replaces ATP bound to the ␥ subunit allosterically activating the kinase, switching on catabolic pathways that produce ATP, and switching off anabolic pathways that consume ATP (17) (18) (19) . In this manner, AMPK serves as an integrator of multiple regulatory signals important in monitoring energy status and maintaining systemic and cellular homeostasis. AMPK activation by changes in the cellular AMP/ ATP ratio represents its classically described mode of regulation; however, it is becoming clear that this "master sensor" can also be activated by AMP independent mechanisms (4). This form of AMPK stimulation occurs when upstream AMPK kinases phosphorylate the ␣ subunit at Thr172. Recently, this mode of AMPK activation has been associated with vascular protective responses to stimuli, wherein AMPK stimulation resulted in protection from apoptosis, endothelial NOS (eNOS) activation in response to shear stress, regulation of inflammation, and maintenance of vascular tone and perfusion (6 -8, 25, 26, 38 -40, 49 ).
An important aspect of signaling specificity involves the subcellular location of component molecules. How AMPK signaling specificity relates to its subcellular location is not well understood. AMPK is generally considered a cytosolic protein with some indication that it traffics to the nucleus depending upon its active state (10, 27) . There is also evidence that AMPK can associate with subcellular membranes, including the plasma membrane, through myristoylation of its ␤-subunit. It was speculated this association occurred through an AMP-regulated myristoyl switching mechanism where myristoylation controlled cytosol to membrane translocation in response to signaling cues. However, no determination was made if AMPK associated with the membrane was restricted to specific membrane compartments (34, 35) . Whether AMPK activity associated with vascular repair is mediated by a unique pool of membrane associated AMPK remains to be determined.
Our present studies build on previous work which supports the idea of location-dependent function and unique pools of AMPK (32) . In lung capillary endothelium, AMP-activated kinase ␣1 (AMPK␣1) is both found in the cytosol and associated with the cell membrane. However, the membrane-bound AMPK␣1 is restricted to the caveolar compartment where it colocalizes with N-cadherin and caveolin-1 (11). These observations suggest this pool of AMPK␣1 serves a specific function, an idea consistent with the microdomain organizing properties of caveolae (2, 23, 41) . Basal levels of active AMPK␣ (pAMPK␣) in PMVECs are high relative to other cell types (11, 24) . Assessment of AMPK activity revealed that constitutive levels of pAMPK␣ were decreased in cells expressing the N-cadherin/GFP fusion protein. Yet, levels of total AMPK␣1 were not altered. Moreover, AMPK was not stimulated by AICAR. Further study revealed that AMPK␣1 no longer associated with N-cadherin in the ⌬N-cad cells or localized to the cell membrane. Thus loss of membrane associated AMPK decreased basal AMPK activity overall and rendered it insensitive to stimulation by its canonical activator, AICAR. These data indicate that the intracellular domain of N-cadherin was involved in localizing AMPK␣1 to the membrane necessary for stimulation by AICAR. This novel finding became more intriguing when resistance and wound repair studies in the ⌬N-cad cells revealed that AMPK was no longer coupled to barrier repair.
AMPK function associated with barrier repair involves a physical link between AMPK␣1 and the intracellular domain of N-cadherin. How N-cadherin and AMPK␣1 interact remains to be determined. This determination is not likely to be a straightforward process since N-cadherin and AMPK␣1 are known to bind a plethora of other proteins (12, 13, 20, 22, 33) . Their association with caveolin-1 also increases the possible number of proteins involved, as well as the likelihood that association of AMPK␣1 with N-cadherin is mediated through linker proteins sequestered to caveolae by the scaffolding functions of caveolins (2, 41) . Caveolins are not the only scaffolding proteins involved in this complex. Cadherins, while best known for their roles as adhesion molecules, also serve as scaffolding proteins. Thus colocalization of AMPK␣1 with N-cadherin to this subcellular region could occur through direct binding of AMPK␣1 to N-cadherin, through linker molecules involving caveolins, or through linker molecules involving N-cadherin. It is also important to note that this protein-protein association appears to be unique among the cadherins. Neither VE-cadherin nor E-cadherin colocalize with AMPK at the membrane or sequester to the caveolar compartment in lung capillary endothelial cells, making it unlikely that either cadherin is involved in this pathway.
Membrane associated AMPK␣1 is not our only observation concerning the importance of subcellular location. Our current finding that N-cadherin localizes to regions of homotypic cell-cell interaction in endothelium provides further support of this concept of location-dependent function. N-cadherin was first described as having a diffuse cortical distribution, and it was suggested its primary role in endothelium was to provide heterotypic adhesion between endothelial cells and underlying smooth muscle cells (43) . In contrast to this view of Ncadherin subcellular location, we found that native N-cadherin in PMVECs resided within discrete areas of cell membrane near regions of endothelial-endothelial cell contact. In keeping with these results, the N-cadherin/GFP fusion protein localized to the membrane near cell-cell borders and did not exhibit random distribution in the bulk membrane, confirming Ncadherin trafficked to a specific region of membrane. Furthermore, this targeting specificity did not require its intracellular domain. Our results are consistent with the notion that a major role for N-cadherin in pulmonary endothelium is to promote endothelial-to-endothelial cell interactions. However, determining the full nature of N-cadherin's role in lung repair will be delayed by the limited availability of the necessary molecular tools.
In conclusion, AMPK␣1 and N-cadherin serve important and coordinated roles in mediating vascular repair. It is likely these roles depend upon the subcellular colocalization of the proteins within a unique membrane compartment. Defining the molecular mechanism(s) involved in this repair process will open new avenues of study directed toward treating vascular diseases such as sepsis and ARDS and suggest activation of AMPK may be a therapeutic alternative to antibiotics. This idea is especially appealing considering the ongoing concern over excessive use of antibiotics and the continued development of bacterial resistance. 
